Reply to P. de Boissieu et al

David R Spigel¹, Afshin Dowlati¹, Yuanbin Chen¹+14

• ¹David R. Spigel, MD, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN; Afshin Dowlati, MD, University Hospitals Seidman Cancer Center and Case Western Reserve University Cleveland, OH; Yuanbin Chen, MD, Cancer and Hematology Centers of Western Michigan, Grand Rapids, MI; Alejandro Navarro, MD, Hospital Universitario Vall d'Hebron and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; James Chih-Hsin Yang, MD, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, Taiwan; Goran Stojanovic, MD, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, Serbia; Maria Jove, MD, PhD, Institut Català d'Oncologia Hospital Duran i Reynals, Barcelona, Spain; Patricia Rich, MD, Southeastern Regional Medical Center, Newnan, GA; Zoran G. Andric, MD, University Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia; Yi-Long Wu, MD, Guangdong Lung Cancer Institute, Guangzhou, China; Charles M. Rudin, MD PhD, Druckenmiller Center for Lung Cancer Research, Memorial Sloan Kettering Cancer Center, New York, NY; Huanyu Chen, PhD, Ipsen, Cambridge, MA; Li Zhang, MPH, Ipsen, Cambridge, MA; Stanley Yeung, PharmD, Ipsen, Cambridge, MA; Fawzi Benzaghou, MD, Ipsen, Cambridge, MA; Luis Paz-Ares, MD, Hospital Universitario 12 de Octubre, H120-CNIO Lung Cancer Unit, Universidad Complutense and Ciberonc, Madrid, Spain; and Paul A. Bunn, MD, University of Colorado School of Medicine, Aurora, CO.